Pegunigalsidase
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Fabry's Disease, Valvular Disease and Infective Endocarditis: A Rare Intersection.
Journal: JACC. Case reports
Published: September 04, 2026
Feasibility and safety of pegunigalsidase alfa infusion during hemodialysis: first case report in a Fabry patient with kidney failure.
Journal: Journal of nephrology
Published: March 13, 2026
Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review.
Journal: Orphanet journal of rare diseases
Published: January 21, 2026
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.
Journal: Orphanet journal of rare diseases
Published: November 12, 2025
Sex-based antibody subclass maturation drives direct enzymatic inhibition in fabry disease patients receiving enzyme replacement therapy.
Journal: Frontiers in molecular biosciences
Published: October 16, 2025
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.
Journal: Frontiers in immunology
Published: October 14, 2025
Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.
Journal: Journal of clinical medicine
Published: May 23, 2025
Progress and Challenges in the Treatment of Fabry Disease.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 09, 2025
Lysosomal storage diseases in North America: a comprehensive review of enzyme therapies and unmet needs.
Journal: Therapeutic advances in rare disease
Published: February 17, 2025
New Drugs Available for Fabry Disease.
Journal: Kidney & blood pressure research
Published: December 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: November 04, 2024
Current status of the immunogenicity of enzyme replacement therapy in fabry disease.
Journal: Orphanet journal of rare diseases
Published: October 10, 2024
Last Updated: 11/08/2026